\-\ Texto\\:\\ \ \(0\)\
\-\ normal\ \(4026\)\
\-\ none\\ to\\ date\ \(2\)\
\-\ intraconal\\ mass\\ lesion\\:\\ marked\\ enlargement\\ of\\ optic\\ nerve\\ and\\ nerve\\ sheath\\ from\\ the\\ back\\ of\\ the\\ globe\\ through\\ the\\ orbit\\,\\ optic\\ \\ canal\\,\\ and\\ extending\\ to\\ the\\ chiasm\\.\ \(0\)\
\-\ optic\\ nerve\\ glioma\ \(11\)\
\-\ \\â\\€\\¢\\ meningioma\ \(7\)\
\-\ \\â\\€\\¢\\ rhabdomyosarcoma\ \(2\)\
\-\ \\â\\€\\¢\\ optic\\ nerve\\ glioma\ \(0\)\
\-\ 14\\ y\\.o\\.\\ boy\\ with\\ gradual\\ visual\\ loss\\ in\\ right\\ eye\ \(1\)\
\-\ up\\ to\\ 1\\/2\\ of\\ pediatric\\ optic\\ nerve\\ gliomas\\ are\\ seen\\ in\\ patients\\ with\\ neurofibromatosis\\ type\\ 1\\ \\(nf\\-1\\)\\.\\ \\ however\\,\\ this\\ patient\\ had\\ careful\\ evaluation\\,\\ and\\ has\\ no\\ stigmata\\ or\\ features\\ of\\ nf\\-1\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.21040989465983118\ \(0\)\
\-\ nerve\\:\\ 0\\.1637737301323035\ \(0\)\
\-\ nf\\-1\\:\\ 0\\.14616187818959966\ \(0\)\
\-\ glioma\\:\\ 0\\.08197178284482108\ \(0\)\
\-\ stigmata\\:\\ 0\\.07308093909479983\ \(0\)\
\-\ intraconal\\:\\ 0\\.06734693376785636\ \(0\)\
\-\ 1\\/2\\:\\ 0\\.06139357432173484\ \(0\)\
\-\ gliomas\\:\\ 0\\.059973027591686726\ \(0\)\
\-\ gradual\\:\\ 0\\.05833312674246057\ \(0\)\
\-\ careful\\:\\ 0\\.05691258001241246\ \(0\)\
\-\ chiasm\\:\\ 0\\.054019668145565206\ \(0\)\
\-\ globe\\:\\ 0\\.052823093853791914\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.05115090679504284\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.050225253848344656\ \(0\)\
\-\ sheath\\:\\ 0\\.05004941021056582\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.05001109632752833\ \(0\)\
\-\ orbit\\:\\ 0\\.045794243802655836\ \(0\)\
\-\ date\\:\\ 0\\.045677977094866574\ \(0\)\
\-\ pediatric\\:\\ 0\\.043777000618873206\ \(0\)\
\-\ visual\\:\\ 0\\.041211446822948875\ \(0\)\
\-\ 14\\:\\ 0\\.04006023847571235\ \(0\)\
\-\ features\\:\\ 0\\.038362045437500825\ \(0\)\
\-\ eye\\:\\ 0\\.038132019224594804\ \(0\)\
\-\ canal\\:\\ 0\\.036116844943555444\ \(0\)\
\-\ enlargement\\:\\ 0\\.03606987666473506\ \(0\)\
\-\ marked\\:\\ 0\\.03547744149600539\ \(0\)\
\-\ meningioma\\:\\ 0\\.034958397196330586\ \(0\)\
\-\ boy\\:\\ 0\\.030901295531127353\ \(0\)\
\-\ type\\:\\ 0\\.030644938599435217\ \(0\)\
\-\ extending\\:\\ 0\\.030560840945104223\ \(0\)\
\-\ back\\:\\ 0\\.029990067397313587\ \(0\)\
\-\ evaluation\\:\\ 0\\.026406795700285188\ \(0\)\
\-\ loss\\:\\ 0\\.026387916728387653\ \(0\)\
\-\ y\\.o\\:\\ 0\\.026238079070071276\ \(0\)\
\-\ through\\:\\ 0\\.02581869168532839\ \(0\)\
\-\ however\\:\\ 0\\.02531242612337309\ \(0\)\
\-\ up\\:\\ 0\\.024445182458023653\ \(0\)\
\-\ patients\\:\\ 0\\.023527389354957722\ \(0\)\
\-\ none\\:\\ 0\\.022550207520297943\ \(0\)\
\-\ 1\\:\\ 0\\.021631131574039435\ \(0\)\
\-\ had\\:\\ 0\\.019615423608943704\ \(0\)\
\-\ lesion\\:\\ 0\\.018516544957451645\ \(0\)\
\-\ seen\\:\\ 0\\.017964123564549895\ \(0\)\
\-\ has\\:\\ 0\\.01707127628185402\ \(0\)\
\-\ normal\\:\\ 0\\.014251196325522351\ \(0\)\
\-\ to\\:\\ 0\\.013629833248180411\ \(0\)\
\-\ from\\:\\ 0\\.013472720352704385\ \(0\)\
\-\ mass\\:\\ 0\\.012643202201569835\ \(0\)\
\-\ are\\:\\ 0\\.012392275239676613\ \(0\)\
\-\ \\:\\:\\ 0\\.012024200170113457\ \(0\)\
\-\ \\,\\:\\ 0\\.011519577256054781\ \(0\)\
\-\ or\\:\\ 0\\.010654497329401144\ \(0\)\
\-\ this\\:\\ 0\\.010224863971426947\ \(0\)\
\-\ right\\:\\ 0\\.009591826692664007\ \(0\)\
\-\ no\\:\\ 0\\.00915366117770002\ \(0\)\
\-\ patient\\:\\ 0\\.009112680116131786\ \(0\)\
\-\ in\\:\\ 0\\.008965898513622445\ \(0\)\
\-\ \\(\\:\\ 0\\.007684699215360218\ \(0\)\
\-\ \\)\\:\\ 0\\.007590826511843671\ \(0\)\
\-\ the\\:\\ 0\\.005882948285260672\ \(0\)\
\-\ and\\:\\ 0\\.005744968268049525\ \(0\)\
\-\ of\\:\\ 0\\.004957608544595252\ \(0\)\
\-\ with\\:\\ 0\\.0024894505551040368\ \(0\)\
\-\ \\.\\:\\ 0\\.001510618557333884\ \(0\)\
